Trial NCT04383574
Publication Wu Z, 2021
Primary outcome on the report: Vaccine-related adverse event (adverse reaction) within 28 days after the administration of each dose of vaccine or placebo; Seroconversion rate of neutralising antibodies to live SARS-CoV-2 at day 28 after the second dose